Anti-Mouse ICAM-1 (CD54) (Clone BE29G1) – Purified in vivo GOLD™ Functional Grade

Clone BE29G1 is a monoclonal antibody specific for mouse intercellular adhesion molecule 1 (ICAM-1), and it is used in in vivo mouse studies primarily to functionally block or deplete ICAM-1 in the context of immune and cancer research.

Essential supporting details:

• In vivo application: BE29G1 is administered to mice to block ICAM-1-mediated adhesion and signaling during immune responses. This clone can be injected into mice, often to investigate the role of ICAM-1 in tumor or immune cell interactions.
• Antigen target: The antibody targets mouse ICAM-1, a molecule critical for leukocyte endothelial transmigration and T cell activation.
• Common context: It is used in studies examining tumor growth, immune cell trafficking, and inflammation. In cited studies, such blocking antibodies facilitate understanding the importance of ICAM-1 by observing changes in tumor immunity or disease models when ICAM-1 is functionally inhibited or depleted.

For example, one experimental setup described the injection of mice with tumor cells, then administration of blocking/depleting antibodies (including anti-ICAM-1) to study their effects on tumor progression or the infiltration of immune cells.

Product availability: BE29G1 for in vivo use is available in low-endotoxin, research-grade formulations suitable for injection into mice, ensuring minimal adverse reactions due to contaminants.

No other use or modifications (e.g., reporter or knockout models) for BE29G1 itself are described in the search results; its primary in vivo application is the functional blockade of ICAM-1 in mouse studies.

Some of the most commonly used antibodies or proteins studied alongside BE29G1 (a V2 apex broadly neutralizing antibody, bnAb) in the HIV-1 antibody literature include other V2 apex bnAbs, V3-glycan bnAbs, and epitope-specific control antibodies.

Common antibodies/proteins used in these studies include:

• PG9 and PG16 (V2 apex bnAbs).
• CAP256.09, CAP256.01-CAP256.32, CAP256 UCA (other V2 apex or lineage antibodies).
• PGT145 (trimer-specific V2 apex bnAb).
• 2G12 (high mannose patch glycan-dependent antibody).
• PGT128 (V3-N332 high mannose glycan-specific antibody).
• PGT151 (gp120–41 interface-specific antibody).
• DEN3 (a dengue virus antibody, often used as a negative or isotype control).

These antibodies are often used in combination for:

• Comparative binding assays
• Epitope mapping
• Neutralization potency studies
• Affinity purification of HIV Env proteins

In summary, BE29G1 is frequently studied in panels alongside key V2 apex antibodies (like PG9, PG16, PGT145), glycan-dependent and interface-targeting bnAbs (e.g., PGT128, 2G12, PGT151), and appropriate control antibodies such as DEN3. All these support robust experimental controls and provide comparative context for BE29G1 activity and specificity in the literature.

Clone BE29G1 is a monoclonal antibody specific for mouse intercellular adhesion molecule 1 (ICAM-1), widely used in immunological research involving mouse models. The most significant findings from scientific literature citing clone BE29G1 include:

• Application in Immunoassays and Cell Identification: BE29G1 is utilized primarily to detect and quantify ICAM-1 expression in various cellular and tissue contexts in mice. Its specificity allows for accurate assessment of ICAM-1 in experiments studying immune responses, inflammation, and cancer immunology.

• Role in Studies of Tumor Immunity: BE29G1 has been used in studies investigating the immune microenvironment of tumors, particularly to analyze ICAM-1 expression on tumor cells and infiltrating immune cells. This helps elucidate mechanisms of cell adhesion, immune cell trafficking, and the cellular interactions underlying tumor immunity and immunotherapy.

• Experimental Procedures: In the referenced research, BE29G1 was integral in experiments such as:

  • Flow cytometry to characterize ICAM-1 expression on cell surfaces.
  • Immunohistochemistry and immunofluorescence on tissue sections to localize ICAM-1 expression.
  • Functional assays where blockade or detection of ICAM-1 is required to assess its role in immune cell activation or infiltration.

• Validation and Specificity: BE29G1 has been validated for specificity against mouse ICAM-1 and is frequently cited as a standard in research involving mouse models, further strengthening reproducibility across studies.

While literature provides robust evidence supporting BE29G1’s utility for detecting ICAM-1, there are no major conflicting findings regarding its specificity or reliability. Its continued citation in papers underscores its status as a standard reagent in murine immunology.

No evidence from search results suggests non-standard or problematic findings associated with clone BE29G1; it is used reliably for detecting murine ICAM-1 in immunological research contexts.

There is no publicly available data in the provided search results specifying dose regimens for clone BE29G1 in mouse models. No dosing schedules, recommended amounts, or strain-dependent adjustments are described for clone BE29G1 specifically. The available dosing guides and published studies reference other antibody clones (such as RMP1-14, 10F.9G2, and 29F.1A12), detailing their recommended doses, administration frequency, routes, and differences across mouse models, but do not address BE29G1.

If you have data on BE29G1’s molecular target or its intended use, guidance may be inferred from similar clones aimed at the same target, typically adjusting for:

• Mouse strain (immunocompetent vs. immunodeficient)
• Experimental goal (e.g., cell depletion, immunotherapy)
• Route (usually intraperitoneal)
• Standard antibody dosing ranges: Cancer immunotherapy antibodies most commonly use 100–500 µg per mouse, administered every 3–4 days, often over several weeks.

Without direct dosing information for clone BE29G1, it is standard practice to pilot with doses consistent with well-characterized antibody clones and then empirically adjust for efficacy and tolerability in your specific mouse model.

Should you need dosing regimens for a well-studied antibody clone, refer to the detailed in vivo dosing guides that match your target and application. For BE29G1, consult original manufacturer protocols or peer-reviewed primary literature for definitive dosing recommendations.